These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519 [TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048 [TBL] [Abstract][Full Text] [Related]
31. Hypoxia and upregulation of hypoxia-inducible factor 1{alpha} stimulate venous thrombus recanalization. Evans CE; Humphries J; Mattock K; Waltham M; Wadoodi A; Saha P; Modarai B; Maxwell PH; Smith A Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2443-51. PubMed ID: 20930171 [TBL] [Abstract][Full Text] [Related]
32. Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Lund EL; Thorsen C; Pedersen MW; Junker N; Kristjansen PE Clin Cancer Res; 2000 Nov; 6(11):4287-91. PubMed ID: 11106245 [TBL] [Abstract][Full Text] [Related]
33. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222 [TBL] [Abstract][Full Text] [Related]
34. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776 [TBL] [Abstract][Full Text] [Related]
35. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Sasaki H; Yukiue H; Kobayashi Y; Nakashima Y; Moriyama S; Kaji M; Kiriyama M; Fukai I; Yamakawa Y; Fujii Y Surg Today; 2001; 31(11):1038-40. PubMed ID: 11766079 [TBL] [Abstract][Full Text] [Related]
36. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Mattern J; Koomägi R; Volm M Anticancer Res; 1997; 17(3C):2249-52. PubMed ID: 9216696 [TBL] [Abstract][Full Text] [Related]
37. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume. Davies MM; Jonas SK; Kaur S; Allen-Mersh TG Br J Cancer; 2000 Mar; 82(5):1004-8. PubMed ID: 10737380 [TBL] [Abstract][Full Text] [Related]
38. Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Bian XW; Du LL; Shi JQ; Cheng YS; Liu FX Anal Quant Cytol Histol; 2000 Jun; 22(3):267-74. PubMed ID: 10872046 [TBL] [Abstract][Full Text] [Related]
39. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T Lupus; 2002; 11(6):348-55. PubMed ID: 12139372 [TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]